Yubo International Biotech Ltd. engages in the supply of products that process, store, and administer therapeutic doses of endometrial stem cells for the treatment of disease and injuries. The company is headquartered in Beijing, Beijing and currently employs 18 full-time employees. The firm focuses on the research and development and application of endometrial stem cells and offers its products and services under the brand VIVCELL. The Company’s product offerings include healthcare products for respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. The firm also offers stem cell related services including cell testing and health management consulting services.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
02/29/2020
Revenue
0
0
0
1
0
0
Revenue Growth (YoY)
--
--
-100%
--
--
--
Cost of Revenue
0
0
0
0
--
--
Gross Profit
0
0
0
0
--
--
Selling, General & Admin
0
1
1
1
0
0
Research & Development
--
--
--
--
--
--
Operating Expenses
1
1
1
2
0
0
Other Non Operating Income (Expenses)
--
--
--
--
0
--
Pretax Income
0
-1
-1
-1
0
0
Income Tax Expense
0
0
0
0
0
0
Net Income
0
-1
-1
-1
0
0
Net Income Growth
--
0%
0%
--
--
--
Shares Outstanding (Diluted)
119.82
119.82
118.72
118.13
38.93
1.18
Shares Change (YoY)
0%
1%
1%
202.99%
3,199%
0%
EPS (Diluted)
0
-0.01
-0.01
-0.01
0.01
-0.11
EPS Growth
-6%
-2%
2%
-200%
-109%
-15%
Free Cash Flow
0
0
0
-1
0
0
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
0%
0%
0%
0%
--
--
Operating Margin
0%
0%
0%
-100%
0%
0%
Profit Margin
0%
0%
0%
-100%
0%
0%
Free Cash Flow Margin
0%
0%
0%
-100%
0%
0%
EBITDA
0
-1
-1
-1
--
--
EBITDA Margin
0%
0%
0%
-100%
--
--
D&A For EBITDA
0
0
0
0
--
--
EBIT
0
-1
-1
-1
0
0
EBIT Margin
0%
0%
0%
-100%
0%
0%
Effective Tax Rate
0%
0%
0%
0%
0%
0%
Follow-Up Questions
What are Yubo International Biotech Ltd's key financial statements?
According to the latest financial statement (Form-10K), Yubo International Biotech Ltd has a total asset of $1, Net loss of $-1
What are the key financial ratios for YBGJ?
Yubo International Biotech Ltd's Current ratio is 0.33, has a Net margin is 0, sales per share of $0.
How is Yubo International Biotech Ltd's revenue broken down by segment or geography?
Yubo International Biotech Ltd largest revenue segment is Health Management and Health Maintenance Services, at a revenue of 604,676 in the most earnings release.For geography, China is the primary market for Yubo International Biotech Ltd, at a revenue of 604,676.
Is Yubo International Biotech Ltd profitable?
no, according to the latest financial statements, Yubo International Biotech Ltd has a net loss of $-1
Does Yubo International Biotech Ltd have any liabilities?
yes, Yubo International Biotech Ltd has liability of 3
How many outstanding shares for Yubo International Biotech Ltd?
Yubo International Biotech Ltd has a total outstanding shares of 119.82